drugset / Trial / NCT05659654
The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)
NaSingle-groupOpen-labelPrevention
Summary
Evaluation of the efficacy and safety of ursodeoxycholic acid in blocking the transmission of infectious novel coronaviruses in a population of medical workers
Timeline
- Start
- 2022-12-16
- Primary completion
- 2023-03-03
- Completion
- 2023-03-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ursodeoxycholic Acid | Small molecule | 500 mg | — |